pomalidomide has been researched along with ribociclib in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (ribociclib) | Trials (ribociclib) | Recent Studies (post-2010) (ribociclib) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 330 | 56 | 322 |
| Protein | Taxonomy | pomalidomide (IC50) | ribociclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 1.1228 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0156 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0235 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0352 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1228 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.0393 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, S; Cao, Y; Dong, Z; Li, M; Li, Y; Liu, Y; Ruan, H; Song, W; Tang, Z; Wang, J; Wang, Y; Wei, M; Wei, Y; Yang, C; Yang, G; Zhao, R; Zhou, Y | 1 |
1 other study(ies) available for pomalidomide and ribociclib
| Article | Year |
|---|---|
First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Humans; Mice, Inbred C57BL; Neoplasms, Experimental; Prodrugs; Proteolysis; Purines; Structure-Activity Relationship; Transcription Factors | 2021 |